Exploring the molecular basis of dsRNA recognition by NS1 protein of influenza A virus using molecular dynamics simulation and free energy calculation

Antiviral Research

Volumn 92, Issue 3, 2011, Pages 424-433

  Pan, Dabo ^a   Sun, Huijun ^a   Shen, Yulin ^c   Liu, Huanxiang ^a,b   Yao, Xiaojun ^a,b  

^a LANZHOU UNIVERSITY   (China)

^b LANZHOU UNIVERSITY   (China)

^c Gansu Computing Center   (China)

Author keywords

Influenza A virus; Molecular dynamics simulation; Molecular mechanics generalized born surface area (MM GBSA); Nonstructural protein 1; Protein RNA interaction

Indexed keywords

DOUBLE STRANDED RNA; MUTANT PROTEIN; NONSTRUCTURAL PROTEIN 1; INS1 PROTEIN, INFLUENZA VIRUS; VIRUS PROTEIN;

ARTICLE; CALCULATION; ENERGY; INFLUENZA VIRUS A; MOLECULAR DYNAMICS; MOLECULAR MECHANICS; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN RNA BINDING; SIMULATION; CHEMICAL STRUCTURE; CHEMISTRY; CONFORMATION; GENETICS; HUMAN; METABOLISM; MUTATION; PROTEIN BINDING; PROTEIN CONFORMATION;

INFLUENZA A VIRUS;

HUMANS; INFLUENZA A VIRUS; MODELS, MOLECULAR; MOLECULAR DYNAMICS SIMULATION; MUTATION; NUCLEIC ACID CONFORMATION; PROTEIN BINDING; PROTEIN CONFORMATION; RNA, DOUBLE-STRANDED; VIRAL NONSTRUCTURAL PROTEINS;

EID: 84862832804     PISSN: 01663542     EISSN: 18729096     Source Type: Journal    
DOI: 10.1016/j.antiviral.2011.09.009     Document Type: Article

References (47)

1. Aramini J.M., Ma L.C., Zhou L., Schauder C.M., Hamilton K., Amer B.R., Mack T.R., Lee H.W., Ciccosanti C.T., Zhao L., Xiao R., Krug R.M., Montelione G.T. Dimer interface of the effector domain of non-structural protein 1 from influenza A virus: an interface with multiple functions. J. Biol. Chem. 2011, 286:26050-26060.
2. Case D.A., Cheatham T.E., Darden T., Gohlke H., Luo R., Merz K.M., Onufriev A., Simmerling C., Wang B., Woods R.J. The amber biomolecular simulation programs. J. Comput. Chem. 2005, 26:1668-1688.
3. Cheng A., Wong S.M., Yuan Y.A. Structural basis for dsRNA recognition by NS1 protein of influenza A virus. Cell Res. 2009, 19:187-195.
4. Chien C.Y., Tejero R., Huang Y., Zimmerman D.E., Rios C.B., Krug R.M., Montelione G.T. A novel RNA-binding motif in influenza A virus non-structural protein 1. Nat. Struct. Biol. 1997, 4:891-895.
5. Chien C.Y., Xu Y., Xiao R., Aramini J.M., Sahasrabudhe P.V., Krug R.M., Montelione G.T. Biophysical characterization of the complex between double-stranded RNA and the N-terminal domain of the NS1 protein from influenza A virus: evidence for a novel RNA-binding mode. Biochemistry 2004, 43:1950-1962.
6. Chong L.T., Duan Y., Wang L., Massova I., Kollman P.A. Molecular dynamics and free-energy calculations applied to affinity maturation in antibody 48G7. Proc. Natl. Acad. Sci. USA 1999, 96:14330-14335.
7. Das K., Aramini J.M., Ma L.C., Krug R.M., Arnold E. Structures of influenza A proteins and insights into antiviral drug targets. Nat. Struct. Mol. Biol. 2010, 17:530-538.
8. Das K., Ma L.C., Xiao R., Radvansky B., Aramini J., Zhao L., Marklund J., Kuo R.L., Twu K.Y., Arnold E., Krug R.M., Montelione G.T. Structural basis for suppression of a host antiviral response by influenza A virus. Proc. Natl. Acad. Sci. USA 2008, 105:13093-13098.
9. de Jong M.D., Tran T.T., Truong H.K., Vo M.H., Smith G.J., Nguyen V.C., Bach V.C., Phan T.Q., Do Q.H., Guan Y., Peiris J.S., Tran T.H., Farrar J. Oseltamivir resistance during treatment of influenza A (H5N1) infection. N. Engl. J. Med. 2005, 353:2667-2672.
10. DeLano, W.L., 2002. The PyMOL Molecular Graphics System. <>. http://www.pymol.org.
11. Dharan N.J., Gubareva L.V., Meyer J.J., Okomo-Adhiambo M., McClinton R.C., Marshall S.A., St George K., Epperson S., Brammer L., Klimov A.I., Bresee J.S., Fry A.M. Infections with oseltamivir-resistant influenza A (H1N1) virus in the United States. JAMA 2009, 301:1034-1041.
12. Essmann U., Perera L., Berkowitz M.L., Darden T., Lee H., Pedersen L.G. A smooth particle mesh Ewald method. J. Chem. Phys. 1995, 103:8577-8593.
13. Hale B.G., Randall R.E., Ortin J., Jackson D. The multifunctional NS1 protein of influenza A viruses. J. Gen. Virol. 2008, 89:2359-2376.
14. Hartley D.M., Nelson N.P., Perencevich E.N. Antiviral drugs for treatment of patients infected with pandemic (H1N1) 2009 virus. Emerg. Infect. Dis. 2009, 15:1851-1852.
15. Hatada E., Fukuda R. Binding of influenza A virus NS1 protein to dsRNA in vitro. J. Gen. Virol. 1992, 73(Pt 12):3325-3329.
16. Hay A.J., Wolstenholme A.J., Skehel J.J., Smith M.H. The molecular basis of the specific anti-influenza action of amantadine. EMBO J. 1985, 4:3021-3024.
17. Hou T., Wang J., Li Y., Wang W. Assessing the performance of the MM/PBSA and MM/GBSA methods. 1. The accuracy of binding free energy calculations based on molecular dynamics simulations. J. Chem. Inf. Model 2011, 51:69-82.
18. Hurt A.C., Holien J.K., Parker M., Kelso A., Barr I.G. Zanamivir-resistant influenza viruses with a novel neuraminidase mutation. J. Virol. 2009, 83:10366-10373.
19. Jorgensen W.L., Chandrasekhar J., Madura J.D., Impey R.W., Klein M.L. Comparison of simple potential functions for simulating liquid water. J. Chem. Phys. 1983, 79:926-935.
20. Kim C.U., Lew W., Williams M.A., Liu H., Zhang L., Swaminathan S., Bischofberger N., Chen M.S., Mendel D.B., Tai C.Y., Laver W.G., Stevens R.C. Influenza neuraminidase inhibitors possessing a novel hydrophobic interaction in the enzyme active site: design, synthesis, and structural analysis of carbocyclic sialic acid analogues with potent anti-influenza activity. J. Am. Chem. Soc. 1997, 119:681-690.
21. Kollman P.A., Massova I., Reyes C., Kuhn B., Huo S., Chong L., Lee M., Lee T., Duan Y., Wang W., Donini O., Cieplak P., Srinivasan J., Case D.A., Cheatham T.E. Calculating structures and free energies of complex molecules: combining molecular mechanics and continuum models. Acc. Chem. Res. 2000, 33:889-897.
22. Krug R.M., Aramini J.M. Emerging antiviral targets for influenza A virus. Trends Pharmacol. Sci. 2009, 30:269-277.
23. Krug R.M., Yuan W., Noah D.L., Latham A.G. Intracellular warfare between human influenza viruses and human cells: the roles of the viral NS1 protein. Virology 2003, 309:181-189.
24. Le Q.M., Kiso M., Someya K., Sakai Y.T., Nguyen T.H., Nguyen K.H., Pham N.D., Ngyen H.H., Yamada S., Muramoto Y., Horimoto T., Takada A., Goto H., Suzuki T., Suzuki Y., Kawaoka Y. Avian flu: isolation of drug-resistant H5N1 virus. Nature 2005, 437:1108.
25. Liu H., Yao X. Molecular basis of the interaction for an essential subunit PA-PB1 in influenza virus RNA polymerase: insights from molecular dynamics simulation and free energy calculation. Mol. Pharmaceut. 2010, 7:75-85.
26. Liu J., Lynch P.A., Chien C.Y., Montelione G.T., Krug R.M., Berman H.M. Crystal structure of the unique RNA-binding domain of the influenza virus NS1 protein. Nat. Struct. Biol. 1997, 4:896-899.
27. Liu Y., Zhang J., Xu W. Recent progress in rational drug design of neuraminidase inhibitors. Curr. Med. Chem. 2007, 14:2872-2891.
28. Lu Y., Wambach M., Katze M.G., Krug R.M. Binding of the influenza virus NS1 protein to double-stranded RNA inhibits the activation of the protein kinase that phosphorylates the elF-2 translation initiation factor. Virology 1995, 214:222-228.
29. Min J.Y., Krug R.M. The primary function of RNA binding by the influenza A virus NS1 protein in infected cells: inhibiting the 2'-5' oligo (A) synthetase/RNase L pathway. Proc. Natl. Acad. Sci. USA 2006, 103:7100-7105.
30. Mishin V.P., Hayden F.G., Gubareva L.V. Susceptibilities of antiviral-resistant influenza viruses to novel neuraminidase inhibitors. Antimicrob. Agents Chemother. 2005, 49:4515-4520.
31. Moscona A. Global transmission of oseltamivir-resistant influenza. N. Engl. J. Med. 2009, 360:953-956.
32. Nemeroff M.E., Barabino S.M., Li Y., Keller W., Krug R.M. Influenza virus NS1 protein interacts with the cellular 30 kDa subunit of CPSF and inhibits 3'end formation of cellular pre-mRNAs. Mol. Cell. 1998, 1:991-1000.
33. Noah D.L., Twu K.Y., Krug R.M. Cellular antiviral responses against influenza A virus are countered at the posttranscriptional level by the viral NS1A protein via its binding to a cellular protein required for the 3' end processing of cellular pre-mRNAS. Virology 2003, 307:386-395.
34. Raju R.K., Burton N.A., Hillier I.H. Modelling the binding of HIV-reverse transcriptase and nevirapine: an assessment of quantum mechanical and force field approaches and predictions of the effect of mutations on binding. Phys. Chem. Chem. Phys. 2010, 12:7117-7125.
35. Rungrotmongkol T., Frecer V., De-Eknamkul W., Hannongbua S., Miertus S. Design of oseltamivir analogs inhibiting neuraminidase of avian influenza virus H5N1. Antiviral Res. 2009, 82:51-58.
36. Russell R.J., Haire L.F., Stevens D.J., Collins P.J., Lin Y.P., Blackburn G.M., Hay A.J., Gamblin S.J., Skehel J.J. The structure of H5N1 avian influenza neuraminidase suggests new opportunities for drug design. Nature 2006, 443:45-49.
37. Ryckaert J.-P., Ciccotti G., Berendsen H.J.C. Numerical integration of the cartesian equations of motion of a system with constraints: molecular dynamics of n-alkanes. J. Comput. Phys. 1977, 23:327-341.
38. Sharon A., Balaraju T., Bal C. A catalytic 3D model development of HIV-integrase and drug resistance understanding by molecular dynamics simulation. Antiviral Res. 2011, 90:A43-A44.
39. Sitkoff D., Sharp K.A., Honig B. Accurate calculation of hydration free energies using macroscopic solvent models. J. Phys. Chem. 1994, 98:1978-1988.
40. Solorzano A., Webby R.J., Lager K.M., Janke B.H., Garcia-Sastre A., Richt J.A. Mutations in the NS1 protein of swine influenza virus impair anti-interferon activity and confer attenuation in pigs. J. Virol. 2005, 79:7535-7543.
41. Srinivasan J., Cheatham T.E., Cieplak P., Kollman P.A., Case D.A. Continuum solvent studies of the stability of DNA, RNA, and phosphoramidate-DNA helices. J. Am. Chem. Soc. 1998, 120:9401-9409.
42. Stouffer A.L., Acharya R., Salom D., Levine A.S., Di Costanzo L., Soto C.S., Tereshko V., Nanda V., Stayrook S., DeGrado W.F. Structural basis for the function and inhibition of an influenza virus proton channel. Nature 2008, 451:596-599.
43. Strockbine B., Rizzo R.C. Binding of antifusion peptides with HIVgp41 from molecular dynamics simulations: quantitative correlation with experiment. Proteins 2007, 67:630-642.
44. von Itzstein M., Wu W.Y., Kok G.B., Pegg M.S., Dyason J.C., Jin B., Van Phan T., Smythe M.L., White H.F., Oliver S.W., et al. Rational design of potent sialidase-based inhibitors of influenza virus replication. Nature 1993, 363:418-423.
45. Wang C., Takeuchi K., Pinto L.H., Lamb R.A. Ion channel activity of influenza A virus M2 protein: characterization of the amantadine block. J. Virol. 1993, 67:5585-5594.
46. Wang W., Riedel K., Lynch P., Chien C.Y., Montelione G.T., Krug R.M. RNA binding by the novel helical domain of the influenza virus NS1 protein requires its dimer structure and a small number of specific basic amino acids. RNA 1999, 5:195-205.
47. Weinstock D.M., Zuccotti G. The evolution of influenza resistance and treatment. JAMA 2009, 301:1066-1069.